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Endogenous mobile genetic elements can give rise to de novo germline or somatic mutations that can have 
dramatic consequences for genome regulation both local and possibly more globally based on the site of 
integration. However if we consider them as ‘normal genetic’ components of the reference genome then 
they are likely to modify local chromatin structure which would have an effect on gene regulation irrelevant 
of their ability to further transpose. As such they can be treated as any other domain involved in a gene x 
environment interaction. Similarly their evolutionary appearance in the reference genome would supply a 
driver for species specific responses/traits. Our recent data would suggest the hominid specific subset of 
retrotransposons, SINE-VNTR-Alu (SVA), can function as transcriptional regulatory domains both in vivo and 
in vitro when analysed in reporter gene constructs. Of particular interest in the SVA element, were the 
variable number tandem repeat (VNTR) domains which as their name suggests can be polymorphic. We and 
others have previously shown that VNTRs can be both differential regulators and biomarkers of disease 
based on the genotype of the repeat. Here, we provide an overview of why polymorphism in the SVA 
elements, in particular the VNTRs, could alter gene expression patterns that could be mechanistically 
associated with different traits in evolution or disease progression in humans.   
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Repetitive DNA in the Genome 
In this article we will use the term variable number tandem repeat (VNTR) to encompass both 
microsatellites and minisatellites however not all tandem repeat domains are polymorphic in repeat copy 
number. Nevertheless there are estimated to be approximately 1 million VNTRs in the human genome 1. 
Their function has been demonstrated to include modulation of alternative splicing, thus altering protein 
isoform levels and effects in gene regulation. It’s the latter of these functions that our group has the most 
experience analysing.  We have demonstrated in several genes involved in monoaminergic transmission in 
the nervous system that, based on copy number, VNTRs can be both biomarkers of predisposition to 
neuropsychiatric disorders direct differential tissue specific and stimulus inducible expression both in vitro 
and in vivo 2-12. We began to address potential VNTRs in the limited number of candidate genes associated 
with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). We identified a 
large tandem repeat domain approximately 10kb 5’ of the major transcriptional start site of the FUS (Fused 
in sarcoma) gene using the UCSC genome bioinformatic site (http://genome.ucsc.edu). Indeed, closer 
inspection of the primary sequence showed the potential for two adjacent VNTRs which varied between 
37-50bp in the size of their repeat sequence. When BLAT was performed using this repeat sequence we 
identified a host of related sequences all sharing significant homology.  This tandem repeat represented the 
central domain of the hominid retrotransposon family termed SINE-VNTR-Alu (SVA).   
 
SVA retrotransposons 
SVA elements only represent 0.13% of the genome, representing ~2700 elements, constituting the 
youngest of the retrotransposable elements in the human genome and are hominid specific. They consist of 
a hexamer repeat (CCCTCT), an Alu-like sequence, a GC-rich VNTR, a SINE and a poly A-tail 13. Many SVA 
elements contain two central GC-rich VNTRs and it should be noted that the flanking hexamer is also a 
VNTR14. Generally SVA elements vary in length from approximately 1000-4000bp with 63% of SVA element 
insertions in the human genome being full length, containing all five domains13, 15. SVA elements are divided 
into subtypes (A-F) by the SINE region and more recently a seventh subtype was identified containing a 5’ 
transduction of the sequence from MAST2 gene referred to as either CpG-SVA, MAST2 SVA or SVA F1 
element 16-18. Similarly to other actively retrotransposing elements SVA elements show inter-individual 
variation in man and can be polymorphic for their absence or presence in the genome. It has been  
estimated that 37.5 % of SVA E elements and 27.6% of SVA F elements are polymorphic for their presence 
in the genome 13 and the average human is estimated to have 56 SVA absence/presence polymorphisms 19.  
As with other retrotransposons much effort has been expended on the retrotransposition event 
itself giving rise to disease.  This has resulted in the identification of at least 8 well characterised diseases in 
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which the retrotransposition event has caused the disease, in the majority of cases by affecting alternative 
slicing15 20. However our hypothesis is that SVA elements would have an effect on epigenetic and 
transcriptional parameters at the locus in which they are found in the human reference genome without 
the need for retrotransposition. These parameters are embedded within the primary sequence of the SVA 
element and in particular the tandem repeat domains.    
SVA elements as a model for Gene x Environment (GxE) interaction in disease progression and evolution 
Our hypothesis is that the SVA element could impart a hominid specific regulatory twist on 
regulation of the gene in which they have inserted (assuming that insertion is not in an exon or destroys 
intron/exon boundaries etc). In the promoter they would act as classical mediators of gene expression. 
Analysis of Human Genome release 19 (Hg19) indicates that of the 2676 SVA elements in the human 
genome, 433 are present within 10kb 5’ of the main transcriptional start site 15. We have published on two 
such promoter domains approximately 8 and 10kb respectively from the major transcriptional start site of 
the nearest gene, namely the PARK 7 and FUS genes. The following points all support a regulatory role for 
SVA elements in the genome: 
1. SVA elements are functional in conventional reporter gene assay both in vitro (cell line) and in vivo 
(chick embryo)14, 21 22. 
2. SVA elements are polymorphic, most clearly via VNTR domains (flanking and internal)14, 15, 21. 
Although SNPs could also exist. 
a. We have previously shown in other genes (as have many others) that VNTRs are both 
polymorphic biomarkers associated with disorders and transcriptional regulatory domains 
in vivo and in vitro2-12. 
b. VNTRs are common regulatory domains in viruses; 
i. They in part control HSV-1 virus latency in dorsal root ganglia (via a similar CCCCTC 
repeat to that found in the flanking sequence of the SVA element)23-25. 
ii. VNTRs are present in the enhancers of many viruses including retroviruses 26, 27.   
3. SVA elements can be associated with active chromatin adjacent to: 
a. Positive affymetrix probe arrays in the human CNS 
b. ENCODE active histone marks 
4. SVA elements  have the potential to form structures which may be strong modulators of genome 
structure/function: 
a. Potential G4 quadruplex14 
b. Strong CpG component approaching the classical requirements to be defined as CpG 
islands, which is consistent with their differential methylation in tumours 28, 29 
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How do hominid specific SVA regulatory domains utilise the existing transcription machinery in the cell 
In our analysis of the FUS SVA element we generated reporter gene constructs that were analysed 
in both the neuroblastoma cell line, SK-N-AS and a chicken embryo model21. In the former, the data was 
consistent with our previous data on the PARK7 SVA element in which we were able to demonstrate that 
the SVA element contained multiple regulatory domains14. This would also be consistent with previous data 
demonstrating promoter function with the SVA F1 element 22. This regulatory analysis was extended with 
the FUS SVA element to demonstrate that this domain supported expression in vivo using the chicken 
embryo model. This is also an example of hominid specific regulatory domains functioning in other species. 
Previously, we have demonstrated the human serotonin transporter VNTR, which is not present in rodents, 
nonetheless supported both tissue specific and differential reporter gene expression in mouse embryos 
which was directed by genotype of the VNTR 12. In this model the expression in the embryo was in the cells 
which at that point in development in the rodent first begin to develop a serotoninergic lineage with 
serotonin transporter (SLC6A4) expression. We hypothesised that the observed reporter expression would 
result from the novel regulatory VNTR which had evolved taking advantage of the existing transcriptional 
machinery in particular subsets of cells that were important for serotonin transporter expression and that 
the VNTR had been maintained in the genome as it contributed a favourable selection in evolution. We 
propose that a similar mechanism would operate at the VNTRs in the SVA element and in part this would 
lead to novel regulatory responses via the SVA element at the adjacent endogenous gene. It should also be 
noted that many VNTRs such as the SLC6A4 VNTR in the mouse transgenic model above are intronic and 
therefore the location of the SVA element to impact such regulatory properties can be quite variable at the 
gene loci.    
The distance of the SVA element from its site of action on a specific promoter or transcriptional 
start site can be quite large. It has been demonstrated by us and others when attempting to reproduce 
endogenous gene expression in transgenic models, that regulatory domains utilised by a locus can be 
100kb+ away from the gene itself.  Our own studies on the endogenous expression of the neuropeptide, 
substance P encoded by the TAC1 gene demonstrated that although the gene itself from 5’ to 3’ UTR was 
8kb, we required a DNA fragment of 350kb to reproduce the appropriate expression patterns30, 31. 
Subsequently our collaborators demonstrated key regulatory domains were as far as 250kb and 100kb 5’of 
the TAC1 gene32. The 350kb TAC1 fragment as a transgenic insertion demonstrated not only the well 
characterised rodent expression of TAC1, but as was the case with the SLC6A4 VNTR, it also demonstrated 
human specific TAC1 expression patterns and we again argued that the DNA was taking advantage of the 
complement of transcription factor that was present in the cells when the DNA in the regulatory regions 
evolved to support distinct transcription profiles for this gene. By the same mechanism we would argue 
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that SVA elements even 100kb away from the transcription start site could modulate transcriptional 
regulation distinct from an allele without a SVA element.    
The recent evolution of SVA elements has imposed restricted sequence variation in each of the SVA 
subclasses; this may allow a concerted response to challenge by groups of SVA elements with similar 
primary sequence based on sequence specific DNA binding proteins. In this manner it might be possible for 
SVA elements containing similar primary sequence such as is present in the hexamer repeat or central 
VNTRs to bind similar transcription factors based on shared consensus DNA binding domains. Thus 
alterations in active transcription factor complement in the cell might modulate several SVA elements by 
the same signal transduction pathways.  
Can SVA elements be responsible for emerging diseases?  
The frequency of SVA element retrotransposition is estimated to be 1:916 births which would 
correspond to 7x106 distinct insertions worldwide in the population 33. These could result in modulation of 
transcriptional properties without modifying protein structure or splicing parameters. Could these 
constitute a proportion of the rare event genetic components that underlie disease processes?  We can 
argue that SVA elements should be assigned a greater role in disease without the retrotransposition event 
and that due in part to the nature of the VNTR elements; they could be biomarkers of predisposition to a 
specific disorder. In our analysis of SVA elements located close to FUS and PARK7 genes, we have addressed 
the polymorphic variation in the VNTRs to establish the range of VNTR repeat number in these domains. 
We found in both of these genes that only one of the central tandem repeat was polymorphic whilst the 
other was a fixed repeat length. We also confirmed in PARK7 that the hexamer was a repeat and 3 length 
variants were observed in the HapMap CEU cohort. For the FUS analysis we performed polymorphic 
analysis in sporadic ALS versus controls (241 and 228 respectively).  The FUS SVA element does not contain 
a flanking hexamer so we analysed only the central repeat domain and found 2 variants. The data implied a 
difference in the homozygous short vs heterozygous long/short SVA element allele carriers in the two 
cohorts for association with sporadic ALS. This might suggest that in a larger cohort we might reach 
significance for these genotypes. A technical problem of such analysis is that PCR over large repeat units is 
not simplistic and each PCR requires significant optimisation, therefore the requirement to do this PCR for 
large cohorts might prove a hindrance to such studies. However, it should be possible to find tagging SNPs 
for SVA elements which demonstrate limited polymorphism as in the FUS SVA element. We have done this 
by converting the long and short SVA element genotype of the individuals from the CEU cohort to ‘SNPs’ so 
they could be uploaded into the Haploview software to allow for identification of tagging SNPs that can be 
used to address correlation with disease in larger cohorts in the future. This approach will allow us in the 
future to generate tagging SNPs for SVA elements for addressing association to disease. This is of course 
dependent on a restricted number of SVA ‘VNTR’ alleles in a specifically targeted SVA element. In the 
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limited number of SVA elements we have addressed, including PARK7 and FUS, we have evidence for two 
major VNTR alleles in the majority with none exhibiting greater variation than PARK7; however the analysis 
is far from complete.  Nevertheless such a strategy may allow for integration of SVA element genotype as a 
correlate of human disease more rapidly than PCR analysis of 1000s of individual SVA elements. 
Concluding Remarks 
Our recent work suggests that SVA elements can in part modulate genome function via their action 
as a transcriptional or epigenetic modulator.  Polymorphism in the VNTRs within these retrotransposons 
demonstrates a mechanism not only for differential regulatory function associated with genotype but a way 
to rapidly integrate polymorphism in the SVA element as a potential biomarker for disease association 
without the requirement for retrotransposition. 
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